Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. - Wikidata - wikimedia - TriplyDB

Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.

Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.

http://www.wikidata.org/entity/Q42502571

about

Parkinson's disease gene therapy: success by design meets failure by efficacy Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery Current prospects and challenges for epilepsy gene therapy The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?Changing channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitability Current prospects for RNA interference-based therapies Electroacoustic stimulation: now and into the future Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10 Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees.Targeting neurons of rat nucleus tractus solitarii with the gene transfer vector adeno-associated virus type 2 to up-regulate neuronal nitric oxide synthase.Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model.Gene therapy for the nervous system: challenges and new strategies.Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.The AAV vector toolkit: poised at the clinical crossroads Clinical applications involving CNS gene transfer.Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease Current advances in using neurotrophic factors to treat neurodegenerative disorders Focusing brain therapeutic interventions in space and time for Parkinson's disease.Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.Recent advances in RNA interference therapeutics for CNS diseases.Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease.Overexpression of the steroidogenic enzyme cytochrome P450 side chain cleavage in the ventral tegmental area increases 3α,5α-THP and reduces long-term operant ethanol self-administration.Gene therapy for Parkinson's disease: where are we now and where are we going?Genetic therapy for the nervous system.Targeted gene therapy for the treatment of heart failure.Targeting the central nervous system with herpes simplex virus / Sleeping Beauty hybrid amplicon vectors.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Small RNA drugs for prion disease: a new frontier.Atoh1 gene therapy in the cochlea for hair cell regeneration.Advances, nuances, and potential pitfalls when exploiting the therapeutic potential of RNA interference.How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease?Challenges for the application of optical stimulation in the cochlea for the study and treatment of hearing loss.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.Non-human primate models of PD to test novel therapies.

P2860

Q26851325-1D306B2A-1D32-4516-8C86-F2ABD2E24D0F Q26851517-BD932BA7-1F64-4398-909F-AD8D37B8B1B3 Q27002627-F97B78D0-7017-45C0-9023-1177F76EBC96 Q27023715-03506C82-A2BD-4FB8-B1A5-B7B1D6D67F8B Q28081164-0EF9F5FA-48F3-45B3-AF6E-BD2D56928039 Q28235733-C00BB16C-8D6C-414B-A4D9-ACBADA8CB69F Q30367376-485AF9BD-31C7-4C5F-A8F0-E900284DA20F Q30531601-0F9D78C8-F8F6-4825-BF5A-4D8AA4673E41 Q33870720-3693045E-19D2-45E1-A416-B1DF488295F8 Q34490776-0A65113C-6A6A-46CC-AE19-4C1B11136CD8 Q34498957-342AF128-9436-42FC-8ED5-F9B623A7FFD0 Q34762396-71AD78EE-26DD-46A7-8755-849EAE6FA3B1 Q35113293-F3302AF1-41CA-432B-81F9-5EB7D965F9A4 Q35136635-2D96A993-AF73-416D-88D2-EBEA6C7E5DB8 Q35184199-D81B6F73-0939-4394-8116-13A165E6E60C Q35340196-C85F3514-DA44-49BC-96AB-C19235122C3D Q35751582-A51107A7-7175-4DF5-A9CB-3A1BF088414B Q35876224-86078C2E-F935-49A5-B3AF-210EE41ACBA3 Q35899850-892B8EF7-B2DC-4601-9492-016A2062E1F4 Q35932749-13A2911C-1796-4EB8-8B6B-C59BB7AA1334 Q36525034-9132C609-756A-44A3-85DC-65662EF79BB6 Q36745293-2307AA7F-0624-4365-A8C2-45D55DC95220 Q36951265-2AB6CCD8-A0DB-4640-8C0A-79DF7BA3A125 Q36983193-0010A3C6-C53E-4BCB-800F-8345EC96BFA7 Q37051728-9DC3F84F-83E6-47A4-B869-3386F3F3874C Q37717621-E6B8B18D-0C5C-41C3-B70E-933859147FD1 Q37810994-CC493A94-0FEC-4484-A85D-7D37E8E8CC79 Q37856565-5322CB07-CFFD-4DEA-9E58-EA18DF9239F1 Q37878086-1BBD53AD-FF34-4A75-9783-729750EE5687 Q37895283-E06AE9FA-4AED-4EF7-8BC5-88D07157F53D Q38075068-D2B819F8-D018-4B29-AF0A-882174051067 Q38091009-06BAFDF7-74A5-4845-B843-8B99FD69EA7F Q38112216-98C5A94C-A663-444A-851B-D8C23077100D Q38121120-5B7C130F-F6FB-4B1F-880E-A4F7ED3783C1 Q38342851-8B2F07EE-5195-44C1-8C54-0A5C1F1D8649 Q38351487-DEFEEC29-DDCA-4EB6-8DCD-CDC3C3753B42 Q38532562-0861FA8E-CFAF-4BEA-AEEC-C74056C08F8D Q38783334-04C81E26-228C-436A-AA9D-A88148753CA2 Q38856794-F2CD0E6B-5926-407D-9D19-82353B54502A Q39229450-2F7E1207-2C8F-4E4E-AF80-4101DC59873A

P2860

Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.

http://www.wikidata.org/entity/Q42502571

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Eight years of clinical improv ...... gene therapy with AAV2-hAADC.

@en

Eight years of clinical improv ...... gene therapy with AAV2-hAADC.

@nl

type

label

Eight years of clinical improv ...... gene therapy with AAV2-hAADC.

@en

Eight years of clinical improv ...... gene therapy with AAV2-hAADC.

@nl

prefLabel

Eight years of clinical improv ...... gene therapy with AAV2-hAADC.

@en

Eight years of clinical improv ...... gene therapy with AAV2-hAADC.

@nl

P1433

Q42502571-630F7FE2-4D8C-484E-893D-66AA3D7147A5

P1476

Q42502571-DE3F33C5-1074-44D5-8213-6D1B7977E7DA

P2093

Q42502571-0A850953-43F0-4497-A691-B6D8A39A34CE

Q42502571-3F3CD697-2352-4C9F-B2D2-D5100FC26FA6

Q42502571-9CA8404D-6A4C-4B63-9C2D-E8F0FBB6E2AF

Q42502571-CB77FCBC-6D5B-4C15-8210-4276E9915687

Q42502571-D74312E3-59F8-4658-9094-20EF2D572CB4

Q42502571-DAAD6D3D-15EA-44DB-BF03-AD9BAC06DB8E

P2860

Q42502571-09AB4FB8-BEDB-4C0A-AD44-90535B12E1FE

Q42502571-1C318B82-6E70-4707-A442-DD613DF7E7E2

Q42502571-31968A5E-534F-4458-957D-557A48BA9DA2

Q42502571-35A14F04-1D5F-4B90-A806-76EC16B6D30B

Q42502571-6A661FC6-E34E-47DD-A128-EE92BF030EB5

Q42502571-7A411637-1335-4310-B6C7-50214BCB8A4D

Q42502571-9282BF9D-7DF0-4F97-A8B1-AB5F15057976

Q42502571-BD930346-0855-4452-8516-88F02EABE6DB

Q42502571-C902C7CB-D28D-42DD-8A6B-D47521DF6057

Q42502571-C9ABB6EC-3BF2-423C-BCCA-E6F8EE11CB7B

P304

Q42502571-EA88262E-B41F-4FBB-A4BB-717BD7FD8290

P31

Q42502571-670FCCF7-82B2-42E2-95F6-9C67CD2BC1EB

P356

Q42502571-7B1E4F50-18BA-41F7-A2DF-F38C805D4A62

P433

Q42502571-BC8F1809-F2EF-46B0-96C2-0120A8FEA26D

P478

Q42502571-1814E516-C362-47BB-96DC-AAD3B886C26A

P50

Q42502571-47C0A0C6-C3F0-4C81-BE29-D44D4D500D50

Q42502571-FC5EC11E-CF27-40D4-A08C-F95A228A0657

P577

Q42502571-1840C649-791F-43F3-81E3-60A848B4EAB7

P5875

Q42502571-15CDC5F5-8785-4E54-A72F-1514DC250FF9

P698

Q42502571-134F368C-C2FC-45BC-946B-890CEBFEE058

P921

Q42502571-3DB9B1AF-E1F7-49EE-9FBA-5CFE627FF43A

P932

Q42502571-4EFDD7A9-FBEF-4CF9-A814-DBEBE9E32A7D

P356

P1433

Molecular Therapy

P1476

Eight years of clinical improv ...... gene therapy with AAV2-hAADC.

@en

P2093

Jamie L Eberling

http://www.w3.org/2001/XMLSchema#string

John Bringas

http://www.w3.org/2001/XMLSchema#string

John Forsayeth

http://www.w3.org/2001/XMLSchema#string

Krystof S Bankiewicz

http://www.w3.org/2001/XMLSchema#string

Philip Pivirotto

http://www.w3.org/2001/XMLSchema#string

Piotr Hadaczek

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.

Gene therapy clinical trials worldwide to 2007--an update.

Current status of gene therapy trials for Parkinson's disease.

A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.

Real-time MR imaging of adeno-associated viral vector delivery to the primate brain.

Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.

Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.

Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.

P304

1458-1461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.106

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Philip Pivirotto

P577

2010-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44657096

http://www.w3.org/2001/XMLSchema#string

P698

20531394

http://www.w3.org/2001/XMLSchema#string

P921

P932

2927057

http://www.w3.org/2001/XMLSchema#string